HealthcareJul 25, 2026

Revance Therapeutics, Inc

Company Profile Analysis

Book Demo Subscribe Now

Revance Therapeutics, Inc - Healthcare showcase

Year Founded & Workforce

1998-12-31

150 Employees

Industry

Healthcare

Services

Revance Therapeutics, Inc Overview

Company Headquarters: California, US

Founded: 1999

Workforce: ~150+

Company Working:

Revance Therapeutics, Inc.is a global healthcare company engaged in the development, manufacture, distribution of botulinum, and other aesthetics & skincare products. The company is a market leader in developing neuromodulators for the treatment of aesthetic and therapeutic conditions. Revance has a strong R&D department, which is providing innovative products. It is pursuing product approval for its blockbuster innovation DaxibotulinumtoxinA for Injection (DAXI) for treatment of crow’s feet, cervical dystonia, adult upper limb spasticity and plantar fasciitis. The company is anticipated to capture significant market share in the therapeutic segment in the botulinum toxin market owing to the strong pipeline.

Strategy

Revance Therapeutics, Inc. is investing a huge amount into conducting clinical trials and developing neuromodulator products for aesthetics and therapeutic purpose. The company aims to become a global leader in the aesthetics and skincare market, and it has been developing the botulinum toxin injectables with the unique dosage form. Additionally, it is focusing on strategic partnerships and collaborations with local players to expand its geographical presence.

Company Snapshot

$0.3M

Revenue

150

Employees

1998-12-31

Founded

California, US

Headquarters

SWOT Analysis

Strengths

Strong research and development department
Innovative products
Strong product pipeline
Skilled workforce

Weaknesses

Financial instability
Low sales
Low sales Financial instability

Opportunities

Opportunities to expand the product portfolio
Geographical expansion through mergers and acquisitions

Threats

As the company is in the clinical trial phase stringent government policies can hamper product launches
As company is in clinical trial phase stringent government policies can hamper the product launch

Key Developments

Date	Approach	Development
December 2018	Agreement	Revance Therapeutics, Inc. entered into an agreement with Fosun Pharmaceutical Group (China) for the manufacture and commercialization of DAXI n China, Hong Kong, and Macau. This agreement is expected to help the company to market its products in the Asia-Pacific region.
February 2018	Collaboration	Revance Therapeutics, Inc. announced a collaboration with Mylan (US) for the development, manufacture, and commercialization of branded biologic products (onabotulinumtoxinA). The collaboration aimed to strengthen its position in the US market.

Product Offering

Revance Therapeutics, Inc
- Facial Injectables
- Clinical Trials

Financial Performance

A plan for every need

Forecast+

Get unlimited access to forecasts, charts, and company data across every research report on Wantstats.

USD200/mo

About the Author

Wantstats Research Team

Wantstats' research desk profiles Revance Therapeutics, Inc as part of our ongoing coverage of the Healthcare sector, drawing on public company data, filings, and market intelligence.

Powering the world's best teams.
From next-gen startups to established enterprises.

See our work in action

Start your data driven journey with us!

Book a Demo Now

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Revance Therapeutics, Inc

Company Headquarters: California, US Founded: 1999 Workforce: ~150+ Company Working: Revance Therapeutics, Inc.is a global healthcare company engaged in the development, manufacture, distribution of botulinum, and other aesthetics & skincare products. The company is a market leader in developing neuromodulators for the treatment of aesthetic and therapeutic conditions. Revance has a strong R&D department, which is providing innovative products. It is pursuing product approval for its blockbuster innovation DaxibotulinumtoxinA for Injection (DAXI) for treatment of crow’s feet, cervical dystonia, adult upper limb spasticity and plantar fasciitis. The company is anticipated to capture significant market share in the therapeutic segment in the botulinum toxin market owing to the strong pipeline.

Starting from

$4,950